Cogent Biosciences, Inc. (COGT) is in Healthcare, Biotechnology, based in United States, listed on NasdaqGS. Market cap 5.22B USD. 52-week range 13.78 to 43.73 USD. Data as of 2026-10-09.
Cogent Biosciences, Inc., a clinical-stage biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor in Phase 3 trial designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal ...